Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.
Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that Ryoncil ® (remestemcel-L) the first mesenchymal stromal cell ...
We were the first lupus organization in the U.S. to support stromal cell research. In partnership with the National Institute of Allergy and Infectious Diseases, we committed nearly $4 million over ...
December 2024, immediately following the approval of the world's first mesenchymal stromal cells clinical trial, the U.S. FDA ...
Researcher suggests compounds secreted by high-risk MSCs that are detectable in the bloodstream could act as biomarkers for ...
The contribution of molecular alterations in bone marrow mesenchymal stromal cells (BM-MSC) to the pathogenesis of acute myeloid leukemia (AML) is poorly understood. Thus we assessed genome-wide ...
Mesoblast’s flagship product, RYONCIL, is the first FDA-approved mesenchymal stromal cell therapy for treating ...
The ASX 200 biotech stock notes that HIE is a devastating type of brain injury caused when a baby's brain does not receive ...
Preliminary work by Farmer and Wang proved that prenatal surgery combined with human placenta-derived mesenchymal stromal cells, held in place with a biomaterial scaffold to form a “patch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback